Werner Engl

2.4k total citations
65 papers, 1.8k citations indexed

About

Werner Engl is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Werner Engl has authored 65 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hematology, 26 papers in Immunology and 9 papers in Genetics. Recurrent topics in Werner Engl's work include Platelet Disorders and Treatments (41 papers), Hemophilia Treatment and Research (30 papers) and Immunodeficiency and Autoimmune Disorders (25 papers). Werner Engl is often cited by papers focused on Platelet Disorders and Treatments (41 papers), Hemophilia Treatment and Research (30 papers) and Immunodeficiency and Autoimmune Disorders (25 papers). Werner Engl collaborates with scholars based in United States, Austria and Germany. Werner Engl's co-authors include Heinz Leibl, Janne Björkander, Martha M. Eibl, Helen Chapel, G Spickett, Oleksandra Stasyshyn, Paul Mulder, Jan A. Hazelzet, Koen F. M. Joosten and C. Erik Hack and has published in prestigious journals such as Blood, Biometrics and Journal of Allergy and Clinical Immunology.

In The Last Decade

Werner Engl

63 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Werner Engl United States 19 1.2k 638 368 267 202 65 1.8k
S. Kary Germany 19 668 0.6× 876 1.4× 223 0.6× 109 0.4× 230 1.1× 23 2.2k
Isabel Badell Spain 24 806 0.7× 265 0.4× 279 0.8× 171 0.6× 255 1.3× 108 1.6k
C. Annaloro Italy 22 605 0.5× 233 0.4× 351 1.0× 139 0.5× 272 1.3× 56 1.3k
P. Vincent Jenkins United Kingdom 24 1.2k 1.0× 246 0.4× 306 0.8× 131 0.5× 87 0.4× 57 1.8k
Nicole Schlegel France 24 1.2k 1.0× 219 0.3× 171 0.5× 339 1.3× 95 0.5× 65 1.7k
Ichiro Tsukimoto Japan 26 1.6k 1.4× 330 0.5× 320 0.9× 270 1.0× 127 0.6× 78 2.2k
M H Schöni Switzerland 6 768 0.6× 497 0.8× 137 0.4× 129 0.5× 93 0.5× 10 1.3k
G. Brehm Germany 13 1.1k 0.9× 841 1.3× 266 0.7× 166 0.6× 139 0.7× 23 1.9k
Bradley P. Dixon United States 18 345 0.3× 783 1.2× 129 0.4× 104 0.4× 88 0.4× 55 1.4k
Gunnar Öberg Sweden 27 1.3k 1.1× 313 0.5× 484 1.3× 136 0.5× 263 1.3× 59 2.1k

Countries citing papers authored by Werner Engl

Since Specialization
Citations

This map shows the geographic impact of Werner Engl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Werner Engl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Werner Engl more than expected).

Fields of papers citing papers by Werner Engl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Werner Engl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Werner Engl. The network helps show where Werner Engl may publish in the future.

Co-authorship network of co-authors of Werner Engl

This figure shows the co-authorship network connecting the top 25 collaborators of Werner Engl. A scholar is included among the top collaborators of Werner Engl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Werner Engl. Werner Engl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manon‐Jensen, Tina, Srilatha Tangada, Cecilie L. Bager, et al.. (2023). Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial. Journal of Thrombosis and Haemostasis. 22(1). 90–100. 4 indexed citations
2.
Sidonio, Robert F., Christine Knoll, Flora Peyvandi, et al.. (2021). Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial. Blood. 138(Supplement 1). 3184–3184. 3 indexed citations
3.
Li, Zhaoyang, Barbara McCoy, Werner Engl, & Leman Yel. (2021). Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin. Journal of Clinical Immunology. 41(6). 1331–1338. 1 indexed citations
4.
Wolfsegger, Martin J., Helmut Schütz, Richardus Vonk, et al.. (2020). Assessing goodness‐of‐fit for evaluation of dose‐proportionality. Pharmaceutical Statistics. 20(2). 272–281. 3 indexed citations
5.
6.
Baek, Hee Jo, Sang Kyu Park, Young Shil Park, et al.. (2019). Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients. Blood Research. 54(3). 198–203. 3 indexed citations
7.
Taki, Masashi, Katsuyuki Fukutake, Tadashi Matsushita, et al.. (2018). Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan. International Journal of Hematology. 109(1). 70–78. 4 indexed citations
8.
Nogami, Keiji, Midori Shima, Katsuyuki Fukutake, et al.. (2017). Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations. International Journal of Hematology. 106(5). 704–710. 7 indexed citations
9.
Wasserman, Richard L., Isaac Melamed, Mark R. Stein, et al.. (2016). Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. Journal of Clinical Immunology. 36(6). 571–582. 41 indexed citations
10.
Mannucci, Pier Mannuccio, Christine L. Kempton, Carolyn M. Millar, et al.. (2013). Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 122(5). 648–657. 87 indexed citations
11.
Wasserman, Richard L., Isaac Melamed, Michal Stein, et al.. (2012). Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD). 2 indexed citations
12.
Wasserman, Richard L., Isaac Melamed, Lisa Kobrynski, et al.. (2011). Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease. Journal of Clinical Immunology. 31(3). 323–331. 64 indexed citations
13.
14.
Varga, Gyula, Heinz Leibl, Zoltán Gasztonyi, et al.. (2006). Efficacy and Safety of the New Intravenous Immunoglobulin IGIV 10% in Adults with Chronic Idiopathic Thrombocytopenic Purpura. Transfusion Medicine and Hemotherapy. 33(6). 509–514. 13 indexed citations
15.
Björkander, Janne, J Nikoskelainen, Heinz Leibl, et al.. (2006). Prospective open‐label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo‐ or agammaglobulinemia. Vox Sanguinis. 90(4). 286–293. 40 indexed citations
16.
Kleijn, Ester D. de, Ronald de Groot, C. Erik Hack, et al.. (2003). Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Critical Care Medicine. 31(6). 1839–1847. 242 indexed citations
17.
Auerswald, Günter, Werner Engl, Christiane Güthner, et al.. (2002). Successful Treatment of Patients with von Willebrand Disease using a High-Purity Double-Virus Inactivated Factor VIII/von Willebrand Factor Concentrate (Immunate®). Seminars in Thrombosis and Hemostasis. 28(2). 203–214. 12 indexed citations
18.
Berntorp, Erik, Pia Petrini, Lilian Tengborn, et al.. (2001). An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients. Haemophilia. 7(4). 360–363. 4 indexed citations
19.
Chapel, Helen, et al.. (2000). The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy. Journal of Clinical Immunology. 20(2). 94–100. 221 indexed citations
20.
Engl, Werner, et al.. (1998). A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 38(6). 540–549. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Kary Breakdown of academic impact, for papers by Isabel Badell Breakdown of academic impact, for papers by C. Annaloro Breakdown of academic impact, for papers by P. Vincent Jenkins Breakdown of academic impact, for papers by Nicole Schlegel Breakdown of academic impact, for papers by Ichiro Tsukimoto Breakdown of academic impact, for papers by M H Schöni Breakdown of academic impact, for papers by G. Brehm Breakdown of academic impact, for papers by Bradley P. Dixon Breakdown of academic impact, for papers by Gunnar Öberg
Rankless by CCL
2026